CY1122566T1 - Παραγωγο 6,7,8,9-tetpaϋδpo-3h-πυραζολo[4,3-f] ισοκινολινης χρησιμο στη θεραπευτικη αντιμετωπιση του καρκινου - Google Patents

Παραγωγο 6,7,8,9-tetpaϋδpo-3h-πυραζολo[4,3-f] ισοκινολινης χρησιμο στη θεραπευτικη αντιμετωπιση του καρκινου

Info

Publication number
CY1122566T1
CY1122566T1 CY20191101110T CY191101110T CY1122566T1 CY 1122566 T1 CY1122566 T1 CY 1122566T1 CY 20191101110 T CY20191101110 T CY 20191101110T CY 191101110 T CY191101110 T CY 191101110T CY 1122566 T1 CY1122566 T1 CY 1122566T1
Authority
CY
Cyprus
Prior art keywords
tetpaydp
pyrazolo
cancer
therapeutic treatment
derivative useful
Prior art date
Application number
CY20191101110T
Other languages
English (en)
Inventor
James Stewart Scott
Bernard Christophe Barlaam
Bin Yang
Thomas Andrew MOSS
Samantha Jayne HUGHES
Johannes Wilhelmus Maria Nissink
Daniel Hillebrand O'DONOVAN
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CY1122566T1 publication Critical patent/CY1122566T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η εφεύρεση αναφέρεται σε ενώσεις του Τύπου (I) και σε φαρμακευτικώς αποδεκτά άλατα αυτής, σε διαδικασίες και ενδιάμεσες ενώσεις που χρησιμοποιούνται για την παρασκευή τους, σε φαρμακευτικές συνθέσεις που τις περιέχουν και στη χρήση τους στη θεραπευτική αντιμετώπιση των κυτταρικών πολλαπλασιαστικών διαταραχών.
CY20191101110T 2016-10-24 2019-10-24 Παραγωγο 6,7,8,9-tetpaϋδpo-3h-πυραζολo[4,3-f] ισοκινολινης χρησιμο στη θεραπευτικη αντιμετωπιση του καρκινου CY1122566T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662411799P 2016-10-24 2016-10-24
US201662435159P 2016-12-16 2016-12-16
PCT/EP2017/076191 WO2018077630A1 (en) 2016-10-24 2017-10-13 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer

Publications (1)

Publication Number Publication Date
CY1122566T1 true CY1122566T1 (el) 2021-01-27

Family

ID=60083331

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20191101110T CY1122566T1 (el) 2016-10-24 2019-10-24 Παραγωγο 6,7,8,9-tetpaϋδpo-3h-πυραζολo[4,3-f] ισοκινολινης χρησιμο στη θεραπευτικη αντιμετωπιση του καρκινου
CY20221100160T CY1125292T1 (el) 2016-10-24 2022-02-23 Παραγωγα 6,7,8,9-tetpaϋδpo-3h-πypazoλo[4,3-f iσοκινολινης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20221100160T CY1125292T1 (el) 2016-10-24 2022-02-23 Παραγωγα 6,7,8,9-tetpaϋδpo-3h-πypazoλo[4,3-f iσοκινολινης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου

Country Status (35)

Country Link
US (4) US10131663B2 (el)
EP (2) EP3433256B1 (el)
JP (2) JP6744489B2 (el)
KR (1) KR102178692B1 (el)
CN (2) CN109843888B (el)
AU (1) AU2017349797B2 (el)
BR (1) BR112019007393A2 (el)
CA (1) CA3040040A1 (el)
CL (1) CL2019001077A1 (el)
CO (1) CO2019003950A2 (el)
CR (1) CR20190204A (el)
CY (2) CY1122566T1 (el)
DK (2) DK3433256T3 (el)
DO (1) DOP2019000104A (el)
EC (1) ECSP19028657A (el)
ES (2) ES2751902T3 (el)
HR (1) HRP20220255T1 (el)
HU (2) HUE045714T2 (el)
IL (1) IL266245B (el)
JO (1) JOP20190090B1 (el)
LT (2) LT3433256T (el)
ME (1) ME03547B (el)
MX (1) MX2019004685A (el)
NI (1) NI201900039A (el)
NZ (1) NZ753459A (el)
PE (1) PE20191078A1 (el)
PH (1) PH12019500830A1 (el)
PL (2) PL3433256T3 (el)
PT (2) PT3433256T (el)
RS (1) RS59445B1 (el)
SG (1) SG11201903182XA (el)
SI (2) SI3433256T1 (el)
TW (1) TWI735681B (el)
UA (1) UA125824C2 (el)
WO (1) WO2018077630A1 (el)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016331065B2 (en) 2015-10-01 2021-04-29 Olema Pharmaceuticals, Inc. Tetrahydro-1H-pyrido(3,4-b)indole anti-estrogenic drugs
EP3440067B1 (en) * 2016-04-08 2021-05-26 F. Hoffmann-La Roche AG Tetrahydroisoquinoline estrogen receptor modulators and uses thereof
TW201803870A (zh) 2016-04-20 2018-02-01 阿斯特捷利康公司 化學化合物
WO2018019793A1 (en) 2016-07-25 2018-02-01 Astrazeneca Ab N-(2-(4-((1r,3r)-3-methyl-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indol-1-yl)phenoxy)ethyl)propan-1-amine derivatives and related compounds as selective down-regulators of the estrogen receptor for treating cancer
CN109843888B (zh) * 2016-10-24 2022-03-01 阿斯利康(瑞典)有限公司 可用于治疗癌症的6，7，8，9-四氢-3H-吡唑并[4，3-f]异喹啉衍生物
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
MD3555097T2 (ro) 2016-12-16 2022-12-31 Janssen Pharmaceutica Nv Compuși imidazo[4,5-d]pirolo[2,3-b]piridină ca inhibitori ai kinazelor Janus
CN110214140B (zh) 2017-01-30 2022-08-30 阿斯利康(瑞典)有限公司 雌激素受体调节剂
WO2019002442A1 (en) * 2017-06-29 2019-01-03 Astrazeneca Ab CHEMICAL COMPOUNDS
WO2019002441A1 (en) * 2017-06-29 2019-01-03 Astrazeneca Ab CHEMICAL COMPOUNDS
NZ764463A (en) * 2017-11-14 2023-07-28 Kind Pharmaceutical Heterocyclic compound and application thereof in medicine
KR20210032936A (ko) 2018-06-15 2021-03-25 리아타 파마슈티컬즈, 아이엔씨. Il-17 및 ror감마의 저해를 위한 피라졸 및 이미다졸 화합물
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
WO2019246461A1 (en) 2018-06-20 2019-12-26 Reata Pharmaceuticals, Inc. Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith
CA3109090A1 (en) 2018-08-17 2020-02-20 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for the treatment of breast cancer
CN109053524A (zh) * 2018-09-11 2018-12-21 山东谛爱生物技术有限公司 一种N-Boc-3-羟基氮杂环丁烷的制备方法
CA3179907A1 (en) * 2020-04-24 2021-10-28 Astrazeneca Ab Dosage regimen for the treatment of cancer
CN115443128A (zh) 2020-04-24 2022-12-06 阿斯利康(瑞典)有限公司 药物配制品
WO2021228210A1 (zh) 2020-05-15 2021-11-18 江苏先声药业有限公司 吡咯烷类化合物及其应用
CN115697987A (zh) * 2020-06-12 2023-02-03 江苏先声药业有限公司 雌激素受体调节剂化合物及其用途
WO2022001971A1 (zh) * 2020-06-28 2022-01-06 南京明德新药研发有限公司 并环吲唑类化合物
CN114105977B (zh) * 2020-08-28 2023-09-01 先声再明医药有限公司 雌激素受体调节剂化合物及其用途
KR20220107752A (ko) 2021-01-26 2022-08-02 충북대학교 산학협력단 피라졸로퀴놀린 유도체 및 이의 항암제로서의 용도
WO2022166980A1 (zh) * 2021-02-08 2022-08-11 贝达药业股份有限公司 杂芳基并哌啶类衍生物及其药物组合物和应用
CN118679157A (zh) * 2021-12-28 2024-09-20 深圳扬厉医药技术有限公司 四氢环庚吲唑化合物的盐型、晶型
WO2024083716A1 (en) 2022-10-17 2024-04-25 Astrazeneca Ab Combinations of a serd for the treatment of cancer
WO2024100236A1 (en) 2022-11-11 2024-05-16 Astrazeneca Ab Combination therapies for the treatment of cancer
US20240180893A1 (en) 2022-11-17 2024-06-06 Astrazeneca Ab Methods of treatment of breast cancer

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
PL213199B1 (pl) 2000-08-10 2013-01-31 Pharmacia Italia Spa Zwiazek bicyklo-pirazolowy, sposób wytwarzania go, jego kompozycja farmaceutyczna, oraz kombinatoryczna biblioteka chemiczna
US20100113502A1 (en) 2005-03-22 2010-05-06 Astrazeneca Ab Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands
FR2884252B1 (fr) 2005-04-08 2007-05-18 Aventis Pharma Sa Nouveaux derives d'isoindoles, compositions les contenant, leur preparation et leurs utilisations pharmaceutiques notamment en tant qu'inhibiteurs d'activites de la proteine chaperone hsp90
AR058223A1 (es) 2005-11-25 2008-01-23 Palau Pharma Sa Un comuesto de derivados de pirazoloisoquinolina, un procedimiento para l a preparacion de dicho compuesto y una composicion farmaceutica que comprende dicho compuesto
EP2223925A1 (en) 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
US20120157402A1 (en) 2009-05-27 2012-06-21 Liangxian Cao Methods for treating brain tumors
TWI671297B (zh) 2009-05-27 2019-09-11 Ｐｔｃ治療公司 治療癌症及非腫瘤病症之方法
WO2010138695A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating neurofibromatosis
RS56042B1 (sr) 2010-06-10 2017-09-29 Seragon Pharmaceuticals Inc Modulatori estrogenih receptora i njihove upotrebe
WO2011159769A2 (en) 2010-06-17 2011-12-22 Aragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
JP5886873B2 (ja) 2010-12-24 2016-03-16 メルク・シャープ・エンド・ドーム・ベー・フェー Ｎ置換アゼチジン誘導体
US9193714B2 (en) 2011-12-14 2015-11-24 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
UY35590A (es) 2013-05-28 2014-11-28 Astrazeneca Ab Nuevos compuestos para el tratamiento del cáncer
BR112015031903A8 (pt) 2013-06-19 2019-12-31 Seragon Pharmaceuticals Inc composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto
CA2915534A1 (en) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
WO2015092634A1 (en) 2013-12-16 2015-06-25 Novartis Ag 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
WO2016097071A1 (en) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Estrogen receptor modulators and uses thereof
CN112457310A (zh) 2014-12-18 2021-03-09 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
US20160175284A1 (en) 2014-12-18 2016-06-23 Genentech, Inc. Estrogen receptor modulators and uses thereof
WO2016174551A1 (en) 2015-04-27 2016-11-03 Pfizer Inc. Anti-estrogenic compounds
EP3303326B1 (en) 2015-05-26 2020-12-16 H. Hoffnabb-La Roche Ag Heterocyclic estrogen receptor modulators and uses thereof
EP3312184A4 (en) 2015-06-16 2019-02-27 Jiangsu Hengrui Medicine Co., Ltd. PIPERIDINE DERIVATIVE AND ITS PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF
CN106518768B (zh) 2015-09-15 2021-07-02 江苏恒瑞医药股份有限公司 丙烯酸类衍生物、其制备方法及其在医药上的应用
AU2016331065B2 (en) 2015-10-01 2021-04-29 Olema Pharmaceuticals, Inc. Tetrahydro-1H-pyrido(3,4-b)indole anti-estrogenic drugs
JP6920295B2 (ja) 2015-11-09 2021-08-18 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト テトラヒドロナフタレンエストロゲン受容体モジュレーター及びその使用
WO2017080338A1 (zh) 2015-11-12 2017-05-18 浙江海正药业股份有限公司 丙烯酸类衍生物、其制备方法及其在医药上的用途
EP3395809A4 (en) 2015-12-22 2019-06-19 Jiangsu Hengrui Medicine Co. Ltd. BENZOPIPERIDIN DERIVATIVE, PRODUCTION METHOD AND MEDICAL USE THEREOF
EP3440067B1 (en) * 2016-04-08 2021-05-26 F. Hoffmann-La Roche AG Tetrahydroisoquinoline estrogen receptor modulators and uses thereof
WO2017182495A1 (en) 2016-04-20 2017-10-26 Astrazeneca Ab Indazole derivatives that down-regulate the estrogen receptor and possess anti-cancer activity
TW201803870A (zh) 2016-04-20 2018-02-01 阿斯特捷利康公司 化學化合物
CN109415388A (zh) 2016-05-06 2019-03-01 路易斯安那泽维尔大学 选择性雌激素受体下调剂(serds)
CN109415361B (zh) 2016-06-29 2022-03-08 浙江海正药业股份有限公司 丙烯酸类衍生物及其制备方法和其在医药上的用途
WO2018019793A1 (en) 2016-07-25 2018-02-01 Astrazeneca Ab N-(2-(4-((1r,3r)-3-methyl-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indol-1-yl)phenoxy)ethyl)propan-1-amine derivatives and related compounds as selective down-regulators of the estrogen receptor for treating cancer
CN107814798B (zh) 2016-09-14 2020-11-03 四川科伦博泰生物医药股份有限公司 3-取代丙烯酸类化合物及其制备方法和用途
US20180072711A1 (en) 2016-09-15 2018-03-15 Arvinas, Inc. Indole derivatives as estrogen receptor degraders
BR102016024814A2 (pt) 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono
CN109843888B (zh) 2016-10-24 2022-03-01 阿斯利康(瑞典)有限公司 可用于治疗癌症的6，7，8，9-四氢-3H-吡唑并[4，3-f]异喹啉衍生物
RS63849B9 (sr) 2016-12-16 2023-06-30 Pfizer Agonisti glp-1 receptora i njihova upotreba
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
KR102276022B1 (ko) 2016-12-16 2021-07-13 일라이 릴리 앤드 캄파니 돌연변이체 idh1 및 idh2 억제제로서의 7-페닐에틸아미노-4h-피리미도[4,5-d][1,3]옥사진-2-온 화합물
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
RU2019121534A (ru) 2016-12-16 2021-01-18 Басф Се Пестицидные соединения
MD3555097T2 (ro) 2016-12-16 2022-12-31 Janssen Pharmaceutica Nv Compuși imidazo[4,5-d]pirolo[2,3-b]piridină ca inhibitori ai kinazelor Janus
ES2866152T3 (es) 2017-01-30 2021-10-19 Chiesi Farm Spa Derivados de tirosina amida como inhibidores de la Rho-quinasa

Also Published As

Publication number Publication date
PE20191078A1 (es) 2019-08-20
LT3433256T (lt) 2019-11-11
JP2019537570A (ja) 2019-12-26
US10131663B2 (en) 2018-11-20
PH12019500830A1 (en) 2019-07-24
HRP20220255T1 (hr) 2022-04-29
CY1125292T1 (el) 2024-02-16
PT3433256T (pt) 2019-10-31
TWI735681B (zh) 2021-08-11
JP6993477B2 (ja) 2022-01-13
PL3433256T3 (pl) 2020-01-31
KR20190066054A (ko) 2019-06-12
CN109843888A (zh) 2019-06-04
JP6744489B2 (ja) 2020-08-19
JP2020186250A (ja) 2020-11-19
WO2018077630A1 (en) 2018-05-03
US20210284636A1 (en) 2021-09-16
JOP20190090B1 (ar) 2023-03-28
EP3640251B1 (en) 2021-12-08
PL3640251T3 (pl) 2022-04-11
DK3640251T3 (da) 2022-03-07
ME03547B (me) 2020-07-20
ES2751902T3 (es) 2020-04-02
UA125824C2 (uk) 2022-06-15
AU2017349797B2 (en) 2020-05-21
US10590130B2 (en) 2020-03-17
ES2907759T3 (es) 2022-04-26
US10961241B2 (en) 2021-03-30
CO2019003950A2 (es) 2019-04-30
EP3640251A1 (en) 2020-04-22
US12077530B2 (en) 2024-09-03
CN114656464A (zh) 2022-06-24
DK3433256T3 (da) 2019-10-28
SG11201903182XA (en) 2019-05-30
KR102178692B1 (ko) 2020-11-13
LT3640251T (lt) 2022-03-10
DOP2019000104A (es) 2019-05-15
IL266245A (en) 2019-06-30
SI3640251T1 (sl) 2022-04-29
BR112019007393A2 (pt) 2019-07-02
EP3433256A1 (en) 2019-01-30
JOP20190090A1 (ar) 2019-04-23
US20180111931A1 (en) 2018-04-26
NI201900039A (es) 2020-05-15
CL2019001077A1 (es) 2019-06-21
EP3433256B1 (en) 2019-08-07
US20190100520A1 (en) 2019-04-04
CA3040040A1 (en) 2018-05-03
SI3433256T1 (sl) 2019-11-29
US20200239467A1 (en) 2020-07-30
ECSP19028657A (es) 2019-04-30
IL266245B (en) 2021-05-31
AU2017349797A1 (en) 2019-05-30
HUE057524T2 (hu) 2022-05-28
HUE045714T2 (hu) 2020-01-28
NZ753459A (en) 2023-01-27
PT3640251T (pt) 2022-02-22
CN109843888B (zh) 2022-03-01
CR20190204A (es) 2019-06-11
MX2019004685A (es) 2019-08-21
RS59445B1 (sr) 2019-11-29
TW201829403A (zh) 2018-08-16

Similar Documents

Publication Publication Date Title
CY1122566T1 (el) Παραγωγο 6,7,8,9-tetpaϋδpo-3h-πυραζολo[4,3-f] ισοκινολινης χρησιμο στη θεραπευτικη αντιμετωπιση του καρκινου
CY1122966T1 (el) 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
CY1122730T1 (el) 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων
CY1123627T1 (el) Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου
PH12017500367B1 (en) Compounds that inhibit mcl-1 protein
EA201691151A1 (ru) Соединения для лечения пациентов с ros1-мутантными раковыми клетками
BR112015029455A8 (pt) compostos químicos, uso, métodos e composições para prevenção ou tratamento de câncer
BR112015020139A2 (pt) compostos terapêuticos e usos dos mesmos
EA201790949A1 (ru) Замещенные 2,4-диаминохинолины в качестве новых противораковых средств
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
CY1122731T1 (el) Διαμορφωτες υποδοχεα οιστρογονων
CR20160527A (es) Derivados de carboxamida
TR201819805T4 (tr) Flavaglin türevleri̇.
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
EA201792264A1 (ru) Способы лечения воспалительных заболеваний
EA201891680A1 (ru) Производные индана в качестве модуляторов mglur7
EA201891027A1 (ru) Фармацевтическая композиция, содержащая производные индола, способ ее получения и применение
EA201792170A1 (ru) Производные индола
EA201600411A1 (ru) Производные пиперидина для применения при лечении или профилактики психиатрических и неврологических состояний
EA201990943A1 (ru) 6,7,8,9-ТЕТРАГИДРО-3H-ПИРАЗОЛО[4,3-f]ИЗОХИНОЛИНОВЫЕ ПРОИЗВОДНЫЕ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ РАКА
EA201992303A1 (ru) СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ БЕЛОК Mcl-1
AR105921A1 (es) Compuestos terapéuticos para el dolor y síntesis de estos
TR201900156T4 (tr) Tüberküloz ve ilgili hastalıkların tedavisi için kinolil hidrazonlar.